Drug intelligence / Profile preview

RA-001

Development stage: Unknown
Lead developer: Red Arrow Therapeutics
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous Injection, Intratumoral Injection

Overview

RA-001 is a pH-activated polymer micelle loaded with interleukin-12 (IL-12), designed to release fully active IL-12 upon sensing intratumoral pH. It is being developed as an immunotherapy for solid tumors. The drug candidate acts as an IL-12 stimulant, aiming to enhance the immune response against cancer cells by leveraging the tumor microenvironment's acidic conditions for targeted activation[1].

Targets

IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on RA-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RA-001.

Explore the full profile